Cited by 56Endometriosis Research and TreatmentEndometrial and Cervical Cancer TreatmentsOvarian cancer diagnosis and treatment

Endometriosis-associated malignant transformation in abdominal surgical scar: A PRISMA-compliant systematic review

Open access
Mihailovici, Anca, Rottenstreich, Misgav, Kovel, Svetlana, Wassermann, Ilan, Smorgick, Noam, Vaknin, Zvi·2017·Medicine

Abstract

BACKGROUND: Endometriosis-associated malignant transformation in abdominal surgical scar (EAMTAS) is a very rare and aggressive phenomenon. Our current article aims to provide a clinical overview, focusing on risk factors affecting survival. METHODS: We performed a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review based on prior reviews and case reports regarding the phenomenon published as abstracts in English, from January 1980 to November 2016. Overall, we identified 47 cases, and we included another case from our institution. We further contacted previous investigators to receive updated follow-up regarding their patients. We analyzed the data, focusing on risk factors that might affect overall survival. RESULTS: All the patients reported in the literature had a uterine surgery, mainly caesarean section. The median time-lag from first surgery to the diagnosis of cancer was about 19 years. Clear-cell carcinoma (CCC) was the most prevalent histology (67%), followed by endometrioid adenocarcinoma (15%). Most of the patients were treated by extensive surgery and chemotherapy and/or radiation. Overall 5 years survival was about 40%. Median overall survival was 42 months (95% confidence interval of [18.7, 65.3]). Although our review is currently the largest in the literature, we cannot draw any statistical significant results due to the limited number of patients reported. According to univariate Cox-regression models, a tendency toward worse prognosis was shown for 3-year disease-free survival clear cell histologic-type (P = .169), and tumor diameter ≥8 cm in nonclear-cell histology, 18 months postdiagnosis (P = .06). CONCLUSION: EAMTAS is a rare and aggressive disease. It is mostly related to cesarean section scars and is diagnosed many years postsurgery. Clear-cell histology tends to endure from the worse prognosis. The treatment is mainly extensive surgery and adjuvant chemotherapy and/or radiotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000009136

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cesarean section endometriosis can be caused by iatrogenic deposition of endometrial cells, glands, and stroma during surgery.

    “Cesarean section endometriosis (CSE) can be caused by the iatrogenic deposition of endometrial cells, glands, and stroma during any time of the surgical procedure.”

    From Cesarean Section: A Potential and Forgotten Risk for Abdominal Wall Endometriosis (2021) · cites this paper as [3]

    The Introduction explains scar endometriosis as iatrogenic transplantation of endometrial tissue to the wound edge during surgery, and defines endometriosis as endometrial glands and stroma outside the uterus. It says this can occur during any surgical procedure, but does not establish the citing sentence’s more specific claim that deposition can occur at any time within a procedure. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Clear cell carcinoma is the most commonly found histology in endometriosis-associated malignant transformation, followed by endometrioid carcinoma.

    “Clear cell carcinoma histology is the most commonly found, followed by endometrioid carcinoma [3].”
  • Clear cell carcinoma arising from endometriotic scars tends to have poor outcomes compared to non-CCC tumors.

    “and it tends to have poor outcomes compared to non-CCC tumors [3].”
  • The 5-year survival rate calculated by Mihailovici et al. (2017) is 40% with a median survival time after diagnosis of 42 months.

    “The 5-year survival rate calculated by Mihailovici et al. (2017) is 40% with a median survival time after diagnosis of 42 months [9].”
  • The average time between initial surgery and diagnosis of endometriotic malignant transformation was 19.3 years, suggesting a slow evolution of the disease.

    “The average time between initial surgery and diagnosis of endometriotic malignant transformation was 19.3 years, which suggested a slow evolution of the disease.”

    From Extra-pelvic endometriosis: a review. (2020) · cites this paper as [29]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mihailovici, A., Rottenstreich, M., Kovel, S., Wassermann, I., Smorgick, N., & Vaknin, Z.
Affiliations
  • Tel Aviv University (IL)
  • Hebrew University of Jerusalem (IL)
Corresponding author
Vaknin, Zvi
Venue
Medicine
Published
2017-12
Volume
96
Issue
49
Pages
e9136
ISSN
0025-7974 (ISSN-L)
OpenAlex
W2772449900
Cited by
56
References
53
Citations by year
2026: 4 · 2025: 5 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 13 · 2020: 8 · 2019: 5 · 2018: 8
FWCI
0.94
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Medicine (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords
clear cell carcinoma, endometrioid carcinoma, cesarean section, uterine surgery, overall survival, prognosis, tumor diameter, disease-free survival, adjuvant chemotherapy, radiotherapy
MeSH terms
Cesarean Section, Cicatrix, Female, Humans, Ovarian Neoplasms, Risk Factors, Gynecologic Surgical Procedures, Uterus, Survival Analysis, Carcinoma, Endometrioid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review